• WM-8014: Precision KAT6A Inhibition for Cancer Biology Resea

  2026-06-29

  WM-8014 enables highly selective, reversible inhibition of KAT6A/B, unlocking targeted oncogene-induced senescence without broad cytotoxicity. This article translates bench insights and protocol enhancements into actionable guidance for researchers leveraging WM-8014 in epigenetic and cancer biology applications.

• CF10 and EdU Synergy Drives Telomere Attrition in CRC Cells

  2026-06-28

  The 2026 study by Das et al. demonstrates that combining CF10, a second-generation fluoropyrimidine polymer, with 5-ethynyl-2′-deoxyuridine (EdU) induces pronounced telomere attrition and mitotic catastrophe in colorectal cancer (CRC) cells. This mechanistic synergy highlights new strategies for targeting telomere maintenance and DNA damage in cancer therapy.

• Quizartinib (AC220): Transforming FLT3 Research in AML

  2026-06-27

  This thought-leadership article examines how Quizartinib (AC220), a potent and selective FLT3 inhibitor, is redefining translational research in acute myeloid leukemia (AML). By integrating advanced mechanistic insight, best-practice experimental approaches, and strategic guidance for resistance and in vivo modeling, we position Quizartinib as a cornerstone for next-generation FLT3-targeted research. The discussion uniquely bridges evidence from recent advances in cell death pathways and selective protein secretion, providing a nuanced vision for future research.

• Salinomycin: Mechanistic Leverage in Hepatocellular Carcinom

  2026-06-26

  This in-depth thought-leadership article explores the mechanistic, translational, and strategic dimensions of Salinomycin—a polyether ionophore antibiotic—within hepatocellular carcinoma (HCC) research. Integrating evidence from foundational molecular studies and recent advances, we chart a course for maximizing workflow rigor, experimental reproducibility, and future impact. The article critically engages with toxicity considerations, unique mechanistic hallmarks, and practical deployment strategies for translational researchers, while also contrasting Salinomycin’s utility against the broader landscape of ionophore and anti-cancer agents.

• PBS (Phosphate-Buffered Saline): Technical Use and Protocols

  2026-06-26

  PBS (Phosphate-Buffered Saline, SKU K2818) provides a sterile, isotonic buffer with physiological pH control, ideal for cell washing, dilution, and in vitro assays in laboratory research. It should not be used in diagnostic or clinical applications, and is optimized for workflows requiring pH and osmolarity stability.

• Pyridostatin TFA: Transforming G-Quadruplex Research Frontie

  2026-06-25

  This article explores how Pyridostatin TFA, a synthetic G-quadruplex DNA structure stabilizer, is reshaping translational research in telomere biology, cancer, and neurodegeneration. We blend mechanistic insight, protocol guidance, and evidence from recent studies—including the impact of G-quadruplexes on TDP-43 toxicity—offering a strategic roadmap for researchers at the intersection of cancer and protein misfolding diseases.

• Murine RNase Inhibitor: Precision RNA Protection for Advance

  2026-06-25

  Murine RNase Inhibitor from APExBIO offers oxidation-resistant RNA protection, crucial for high-sensitivity applications like real-time RT-PCR and cDNA synthesis. Its unique stability under low reducing conditions gives researchers new flexibility and reliability in preserving RNA integrity across complex experimental designs.

• CD40–STING–TRAF2 Axis Drives B Cell Activation in ESCC TLS

  2026-06-24

  This study elucidates how competitive binding between CD40 and STING with TRAF2 regulates IRF4-mediated B cell activation within tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma (ESCC). The findings reveal a mechanistic pathway underpinning TLS-driven antitumor immunity and offer new directions for biomarker discovery and therapeutic targeting.

• E. coli Uracil-DNA Glycosylase (UDG): Technical Lab Guidance

  2026-06-23

  E. coli Uracil-DNA Glycosylase (UDG) enables precise removal of uracil from DNA, addressing PCR contamination and supporting DNA repair research. It is not appropriate for RNA, very short oligonucleotides, or any diagnostic or medical workflows.

• Patient-Derived Gastric Cancer Assembloids Reveal Microenvir

  2026-06-23

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with autologous stromal cell subpopulations, enabling more accurate recapitulation of tumor heterogeneity and microenvironmental influences. The model demonstrates that stromal components significantly impact gene expression and drug response, providing a superior platform for studying drug resistance mechanisms and optimizing personalized therapies.

• Sulfisomidine in Pertussis: Clinical Pharmacology and Transl

  2026-06-22

  This article reviews the landmark study on sulfisomidine (sulfamethin) for the treatment of pertussis, highlighting its clinical application, pharmacokinetics, and safety profile in infants. Key findings include effective blood concentration maintenance, rapid urinary excretion, and a favorable safety outcome in a high-risk pediatric cohort, providing a foundation for both clinical and biochemical research on sulfonamide antibacterial agents.

• NF 449: Redefining Platelet Research with Precision Antagoni

  2026-06-22

  Explore how NF 449, a highly selective purinergic receptor antagonist, empowers translational researchers to dissect platelet activation mechanisms and advance next-generation antithrombotic strategies. This article delivers mechanistic insights, actionable protocol guidance, and a visionary translational outlook—anchored by the latest evidence and practical scenarios for optimizing platelet studies.

• Fosinopril Sodium: Applied ACE Inhibitor Workflows in CVD Mo

  2026-06-21

  Fosinopril sodium stands out as a third-generation ACE inhibitor with dual renal and hepatic elimination, enabling nuanced modeling of hypertension and cardiovascular disease. This article delivers actionable workflow enhancements, troubleshooting strategies, and comparative insights to empower translational researchers leveraging APExBIO’s high-purity Fosinopril sodium in advanced bench protocols.

• DAPT (GSI-IX): Unlocking Notch Pathway Control for Regenerat

  2026-06-20

  Explore how DAPT (GSI-IX) advances regenerative medicine by enabling precise Notch pathway inhibition. This article uniquely analyzes its role in epithelial cell fate and translational research, grounded in recent scientific breakthroughs.

• Rottlerin as a PKCδ Inhibitor: Mechanisms, Apoptosis, and As

  2026-06-19

  Explore how Rottlerin, a selective PKC inhibitor, enables advanced apoptosis and cell signaling research. This comprehensive guide reveals mechanistic insights and assay design strategies beyond standard protocols.

450 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page